Department of Psychology and The Center for Neuroscience, University of Colorado at Boulder, Boulder, CO, USA.
Neuroscience. 2009 Dec 29;164(4):1821-32. doi: 10.1016/j.neuroscience.2009.09.046. Epub 2009 Sep 27.
Spinal cord microglial toll-like receptor 4 (TLR4) has been implicated in enhancing neuropathic pain and opposing morphine analgesia. The present study was initiated to explore TLR4-mediated pain modulation by intrathecal lipopolysaccharide, a classic TLR4 agonist. However, our initial study revealed that intrathecal lipopolysaccharide failed to induce low-threshold mechanical allodynia in naive rats, suggestive that TLR4 agonism may be insufficient to enhance pain. These studies explore the possibility that a second signal is required; namely, heat shock protein-90 (HSP90). This candidate was chosen for study given its known importance as a regulator of TLR4 signaling. A combination of in vitro TLR4 cell signaling and in vivo behavioral studies of pain modulation suggest that TLR4-enhancement of neuropathic pain and TLR4-suppression of morphine analgesia each likely require HSP90 as a cofactor for the effects observed. In vitro studies revealed that dimethyl sulfoxide (DMSO) enhances HSP90 release, suggestive that this may be a means by which DMSO enhances TLR4 signaling. While 2 and 100 microg lipopolysaccharide intrathecally did not induce mechanical allodynia across the time course tested, co-administration of 1 microg lipopolysaccharide with a drug that enhances HSP90-mediated TLR4 signaling now induced robust allodynia. In support of this allodynia being mediated via a TLR4/HSP90 pathway, it was prevented or reversed by intrathecal co-administration of a HSP90 inhibitor, a TLR4 inhibitor, a microglia/monocyte activation inhibitor (as monocyte-derived cells are the predominant cell type expressing TLR4), and interleukin-1 receptor antagonist (as this proinflammatory cytokine is a downstream consequence of TLR4 activation). Together, these results suggest for the first time that TLR4 activation is necessary but not sufficient to induce spinally mediated pain enhancement. Rather, the data suggest that TLR4-dependent pain phenomena may require contributions by multiple components of the TLR4 receptor complex.
脊髓小胶质细胞 Toll 样受体 4(TLR4)被认为可以增强神经病理性疼痛并拮抗吗啡的镇痛作用。本研究旨在通过鞘内给予脂多糖(一种经典的 TLR4 激动剂)来探索 TLR4 介导的疼痛调节。然而,我们的初步研究表明,脂多糖鞘内给药不能在未处理的大鼠中诱导低阈值机械性痛觉过敏,提示 TLR4 激动可能不足以增强疼痛。这些研究探索了需要第二信号的可能性;即热休克蛋白 90(HSP90)。选择该候选物进行研究是因为它作为 TLR4 信号转导调节剂的重要性。TLR4 增强神经病理性疼痛和 TLR4 抑制吗啡镇痛的体外 TLR4 细胞信号转导和体内疼痛调节行为研究表明,TLR4 增强神经病理性疼痛和 TLR4 抑制吗啡镇痛作用都可能需要 HSP90 作为观察到的作用的辅助因子。体外研究表明,二甲基亚砜(DMSO)增强 HSP90 的释放,提示这可能是 DMSO 增强 TLR4 信号转导的一种方式。虽然鞘内给予 2 和 100μg 脂多糖在测试的时间过程中没有引起机械性痛觉过敏,但与增强 HSP90 介导的 TLR4 信号转导的药物共同给予 1μg 脂多糖现在诱导了强烈的痛觉过敏。支持这种痛觉过敏是通过 TLR4/HSP90 途径介导的,它可以通过鞘内共同给予 HSP90 抑制剂、TLR4 抑制剂、小胶质细胞/单核细胞激活抑制剂(因为单核细胞衍生细胞是表达 TLR4 的主要细胞类型)和白细胞介素-1 受体拮抗剂(因为这种促炎细胞因子是 TLR4 激活的下游后果)来预防或逆转。这些结果首次表明,TLR4 激活是必要的,但不足以诱导脊髓介导的疼痛增强。相反,数据表明 TLR4 依赖性疼痛现象可能需要 TLR4 受体复合物的多个组成部分的贡献。